Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 1.

Mechanisms induced by rosmarinic acid in different cancer cell lines (in vitro)

Cancer type Cell Line Treatment concentrations Mechanism of action References
HCC Hep-G2 0-320 µM Induction of apoptosis, caspase activation and inhibition of cell migration and invasion Jin et al., 2020
SMMC-7721 0-100 µmol/L Inhibit PI3K/AKT pathway Wang et al., 2019
Hep-G2 100, 200 and 400 µM Inhibits PI3K/Akt/NF- κB pathway An et al., 2021
CRC

CT26

HCT116

0-200 µM Activation of AMPK Han et al., 2018
HT-29 - Inhibition of p38/AP-1 pathway and EMT by miR-1225-5p Yang et al., 2021

HCT-8

HCT-116

0,75 and 150 µmol/L Suppression of miR-155 leading to an anti-Warburg effect Xu et al., 2016
Pancreatic cancer

PATU-8988

MIA PaCa-2

Panc-1

BxPC-3

0-600 µM Inhibition of Gli1 expression and target proteins Zhou et al., 2022

Panc-1

SW1990

0-200 µM Elevated expression of miR-506 Han et al., 2019
Breast cancer

MDA-MB-468

MDA-MB-231

0-500 µM Modulating extrinsic and intrinsic caspase-independent apoptosis Messeha et al., 2020
MCF-7 1.5, 15 and 50 µM Hindering MDM2, negative regulator of p53 Juskowiak et al., 2018
Ovarian cancer OVCAR-3 0-160 µM

Regulation of lncRNA

MALAT-1

Zhang et al., 2018

SKOV-3

TOV-21G

0, 20 and 40 µM (RAME) Inhibiting FOXM1 and FOXM1 target genes Lim et al., 2020
Cervical cancer

HeLa

SiHa

0-80 µM (RAME) Inhibition of mTOR/S6K1 pathway Nam et al., 2019
Renal carcinoma 786-O 0, 25, 50, and 100 μM Downregulated FAK phosphorylation Su et al., 2016
NSCLC

A549

A549 DPP (cisplatin-resistant)

0-200 µg/mL Activation of JNK pathway Liao et al., 2020
Gastric cancer SGC7901/5-Fu 12.5 to 100 µg/mL Reversal of chemoresistance by inhibiting miR-6785-5p Yu et al., 2019
MKN45 0-600 µM miR-155 mediated inhibition of the Warburg effect Han et al., 2015
Prostate cancer

PC-3

DU-145

25-300 µM Inhibition of HDAC2 Jang et al., 2018
Oral cancer SCC-15 0-180 µM Oxidative ER stress Luo et al., 2020
Glioma

U251

U343

0, 100, 200 and 400 µM Inhibition of PI3K/Akt/NF-κB Liu et al., 2021
U-78 MG 0-1000 µM HSP27 suppression Şengelen and Önay-Uçar, 2018
Osteosarcoma

MG63

U2OS

0, 12.5, 25, and 50 µg/mL Suppression of oncogene DJ-1 Ma et al., 2020
Melanoma A375 0, 50, 100 and 200 µg/mL Suppress ADAM17 expression Huang et al., 2021
Leukemia NP4 40 µM Enhance ARTA-induced macrophage differentiation Heo et al., 2015

CCRF-CEM

Resistant CEM/ADR500

3-100 µM Inhibition of NF- κB Wu et al., 2015
Biomolecules & Therapeutics 2024;32:38~55 https://doi.org/10.4062/biomolther.2023.054
© Biomolecules & Therapeutics